Hemab Therapeutics Holdings, Inc. (COAG) — Stock Score Summary

Hemab Therapeutics Holdings, Inc. (COAG) has a MoatMap StockRank of 14/100 based on Quality (32/100), Value (35/100), and Momentum (32/100) factor scores. The current signal is STRONG SELL. Hemab Therapeutics is an early-stage biotechnology company focused on blood disorders. It lacks the commercial validation, pricing power, and steady cash flows of a quality compounder, making it highly speculative and unsuitable for our concentrated portfolio.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing first-in-class prophylactic therapeutics for serious bleeding disorders. The company's competitive advantage is its focus on targeting under-served, rare bleeding conditions using bispecific antibodies and engineered proteins. It operates as a highly specialized niche player in the hematology space.

Key Financial Metrics

Price$27.00
Market Cap$1.3B
P/E (Forward)-10.93
Price/Book-0.14
Return on Equity-47.0%
Return on Invested Capital-38.1%
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-40M

Hemab Therapeutics Holdings, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Hemab Therapeutics Holdings, Inc.’s (COAG) StockRank?
MoatMap’s StockRank for Hemab Therapeutics Holdings, Inc. (COAG) is 14/100, with a Strong Sell signal. It is a composite of Quality (32), Value (35), and Momentum (32) factor ranks across MoatMap’s 19,000+ stock universe.
Does Hemab Therapeutics Holdings, Inc. have an economic moat?
Hemab Therapeutics Holdings, Inc. (COAG) has a Quality factor score of 32/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hemab Therapeutics Holdings, Inc. a buy, hold, or sell?
MoatMap’s current signal for Hemab Therapeutics Holdings, Inc. (COAG) is Strong Sell, based on a StockRank of 14/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Hemab Therapeutics Holdings, Inc. in?
Hemab Therapeutics Holdings, Inc. (COAG) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCOAG deep dive reportAI ChampionsHow we score stocksSense-check another stock